医学
血脂异常
他汀类
羟甲基戊二酰辅酶A还原酶抑制剂
低密度脂蛋白胆固醇
动脉粥样硬化性心血管疾病
内科学
重症监护医学
胆固醇
疾病
作者
Wang Zhao,Xi‐Long Zheng,Zenan Jiang,Xiaobo Liao,Shui‐Ping Zhao
标识
DOI:10.1016/j.ijcard.2017.06.105
摘要
Background This study investigated the prevalence of atherogenic dyslipidemia (AD) in Chinese outpatients whose low-density lipoprotein cholesterol (LDL-C) levels reached the goals with statin monotherapy and evaluated the characteristics of these patients. Methods An analysis of the Dyslipidemia International Survey-China study that was carried out at 122 hospitals in China. Among patients reaching their LDL-C goals, the presence of AD was defined as triglyceride levels ≥1.7 mmol/L and/or low levels of high-density lipoprotein cholesterol (men: <1.0 mmol/L; women: <1.3 mmol/L). Results 22,039 patients receiving statin monotherapy were analyzed. According to the American National Cholesterol Education Program Adult Treatment Panel III, 13,088 patients reached LDL-C goals, and 7134 patients of them had AD. Age, male gender, BMI, sedentary lifestyle, diabetes mellitus, ischemic cerebrovascular disease, serum uric acid levels, and fasting plasma glucose (all P < 0.05) were independently associated with AD. Based on the Chinese guideline for the management of dyslipidemia, 13,551 patients reached LDL-C goals, and 7719 patients of them had AD. Age, male gender, BMI, sedentary lifestyle, coronary heart disease, serum uric acid levels, and fasting plasma glucose (all P < 0.05) were independently associated with AD. The intensity of statin therapy did not affect the prevalence of AD. Conclusion There was a high prevalence of AD in Chinese patients with optimal statin treatment. Some risk factors associated with AD were identified, but these factors were slightly different according to two criteria/guidelines. The intensity of statin therapy did not reduce the prevalence of AD. A combination lipid therapy may be more suitable for Chinese patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI